EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden

BACKGROUND: The development of EuroQol-5 dimensions (EQ-5D) utility over time in rheumatoid arthritis (RA) patients, treated with biologics other than tumour necrosis factor inhibitors (TNFi), based on the standard British (UK) and the new Swedish (SE) EQ-5D preference sets, has not been previously...

Descripción completa

Detalles Bibliográficos
Autores principales: Gülfe, Anders, Wallman, Johan K., Kristensen, Lars Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759951/
https://www.ncbi.nlm.nih.gov/pubmed/26892115
http://dx.doi.org/10.1186/s13075-016-0950-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759951/
https://www.ncbi.nlm.nih.gov/pubmed/26892115
http://dx.doi.org/10.1186/s13075-016-0950-0

Ejemplares similares